Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small-cell lung cancer.
PURPOSE
Nab-paclitaxel [nab-P, 130-nm albumin-bound paclitaxel particles] is a new solvent-free paclitaxel that allows for high intratumoral concentration and has been approved for use in various solid tumours. The aim of our study was to evaluate the efficacy and safety of nab-paclitaxel in the treatment of advanced non-small-cell lung cancer [NSCLC].


PATIENTS AND METHODS
We assessed 101 Chinese patients who were diagnosed with Stage IIIB or IV NSCLC from August 2009 to November 2014.The patients were injected with nab-paclitaxel [260 mg/m2 , day1] with or without platinum. Patients who completed more than two treatment cycles were assessed for response and survival. All patients were assessed for adverse events.


RESULTS
The efficacy was evaluated in 79 patients; the overall response rate was 32.9%, and the disease control rate was 89.9%. Subgroup analysis found patients with squamous cell carcinoma, and combination therapies showed better outcomes. The median progression-free survival was 5.3 months [95%CI: 4.6-5.9], and the median overall survival was 8.9 months [95%CI: 6.1-11.6]. The main grades 3/4 adverse events were peripheral neuropathy [5.9%], leukopenia [5.0%], and anaemia [3.0%]. Additionally, severe abnormal hepatic function [2.0%], alopecia [2.0%], thrombocytopenia [1.0%] and fatigue [1.0%] could also be identified in some patients.


CONCLUSION
The nab-paclitaxel chemotherapy could achieve significant tumour responses and encourage survival in advanced NSCLC patients with tolerable toxicities. Further clinical studies are needed to explore the optimal therapy regimen and target users.
['Zeng|Junli|J|', 'Yin|Jie|J|', 'Yuan|Dongmei|D|', 'Yang|Wen|W|', 'Liang|Wenjun|W|', 'Wu|Guannan|G|', 'Song|Yong|Y|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D000418:Albumins D000971:Antineoplastic Combined Chemotherapy Protocols D044466:Asians D002289:Carcinoma, Non-Small-Cell Lung D003131:Combined Modality Therapy D018572:Disease-Free Survival D005260:Female D006801:Humans D007262:Infusions, Intravenous D008175:Lung Neoplasms D008297:Male D008875:Middle Aged D009367:Neoplasm Staging D017239:Paclitaxel D016896:Treatment Outcome D050257:Tubulin Modulators
advanced non-small-cell lung cancer efficacy safety nab-paclixale